Form 4: United Therapeutics CEO Sells Shares Under 10b5-1 Plan

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, exercised stock options and sold resulting shares totaling 9,500 under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), reported transactions on March 25, 2026.
• Exercised 9,500 stock options at an exercise price of $146.03 per share.
• Simultaneously sold 9,500 shares of common stock in multiple transactions at weighted average prices ranging from $536.97 to $548.5237.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
• Following these transactions, direct beneficial ownership of common stock decreased from 50,013 to 40,513 shares.
• Remaining derivative securities beneficially owned are 69,000 stock options.
• The 10b5-1 plan is set to continue until the earlier of the exercise of 1,734,410 stock options (expiring March 17, 2027) or December 31, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it's an insider sale, it's pre-planned and at a significant profit, which is a normal part of executive compensation and personal financial management, rather than a signal of negative company performance.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a planned and systematic approach to share disposition rather than an immediate reaction to market conditions.
• The sale prices for the common stock (ranging from $536.97 to $548.5237) are significantly higher than the exercise price of the options ($146.03), indicating a substantial profit for the insider.

Negatives

• The CEO's direct beneficial ownership of common stock decreased by 9,500 shares, which could be interpreted as a reduction in direct exposure to the company's equity.

Future Outlook

The filing indicates a pre-arranged 10b5-1 trading plan is in place, which will continue until the earlier of the exercise of 1,734,410 stock options or December 31, 2026, suggesting further planned insider transactions.

Industry Context

StockSavvy.ai notes that insider sales, particularly by a CEO, are common for compensation and diversification purposes, especially when executed under a Rule 10b5-1 plan. This type of planned sale typically does not signal a change in the company's fundamental outlook but rather a personal financial management decision.

Stakeholder Impact

• Shareholders: The sale by the CEO could be viewed with slight caution, but the pre-arranged nature mitigates concerns about immediate negative sentiment. The significant profit realized by the CEO from option exercise and sale could be seen as a positive indicator of past share price appreciation.

Next Steps

• The 10b5-1 trading plan is expected to continue until the earlier of the exercise of 1,734,410 stock options or December 31, 2026, implying further planned transactions by the reporting person.

Key Dates

Recommendation

This Form 4 filing reports routine insider transactions (option exercise and sale) executed under a pre-arranged 10b5-1 plan. Such transactions are typically for personal financial planning and diversification, not an indication of the company's future prospects. The significant profit realized by the CEO from the option exercise is positive, but the overall impact on the company's fundamentals or future outlook is minimal. Therefore, a "hold" recommendation is appropriate as this filing alone does not provide new information to warrant a change in investment thesis.

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Share Sale, CEO, Biotechnology, Pharmaceuticals